Fortis Memorial Research Institute, Gurugram, in collaboration with Agilus Diagnostics, the diagnostics arm of Fortis Healthcare, has launched its second Ion Torrent Genexus system, marking a significant step forward in enhancing precision cancer diagnostics in India.

By harnessing the power of Next-Generation Sequencing (NGS) technology, the Genexus platform delivers faster, more targeted genomic insights, empowering clinicians to make timely, data-driven decisions for cancer patients.

With this new capability, patients can now access:

• Liquid biopsy results within 24 hours
• Myeloid NGS results within 72 hours
• Minimal residual disease testing within 5 days

Dr Rahul Bhargava, Principal Director & Head, Haematology and BMT at Fortis Gurugram, emphasised the clinical importance of this advancement, saying, "Genomics is not the future anymore - it is the present. Every mutation we detect tells a story, guiding more precise and effective treatment decisions. With faster and deeper insights, we are not only making better treatment decisions but also giving our patients a genuine shot at survival and long-term remission."

Dr Anand K, MD & CEO of Agilus Diagnostics, added, “With the second Genexus system, we are better positioned to expand access to advanced molecular diagnostics and deliver actionable insights faster. This is a crucial step toward personalised medicine for Indian cancer patients.”

This strategic partnership demonstrates how we are using the power of technology and innovation to enhance clinical outcomes, elevate patient experience, and catalyse positive change in the healthcare ecosystem.